Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 432

Sort by

Sort Order Select

Journal Articles

An IgA plasmacytoma: a rare and distinct form of plasmacytoma

Huan-You Wang, Aaron M. Goodman

Blood (2020) 135 (17): 1505.

https://doi.org/10.1182/blood.2020004978

Published: 2020

Journal Articles

Cutaneous plasmablastic plasmacytoma

Alfred Chung, Michaela Liedtke

Blood (2019) 134 (23): 2116.

https://doi.org/10.1182/blood.2019002821

Published: 2019

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Amandeep Godara, MD, Ping Zhou, MD PhD, Benjamin Rosenthal, BS, Adin Kugelmass, BSc, Denis Toskic, BS, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4409.

https://doi.org/10.1182/blood-2019-126988

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow Samples

Hadrian Mendoza, BS, Christopher Tormey, MD, Alexa J. Siddon, MD

Blood (2019) 134 (Supplement_1): 5223.

https://doi.org/10.1182/blood-2019-121747

Published: 2019

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Nicola Giuliani, Silvia Valtorta, PhD, Martina Chiu, PhD, Denise Toscani, PhD, Andrea Sartori, PhD, Angela Coliva, PhD, Arianna Brevi, Stefania Battaglia, MS, Emanuela Vicario, PhD, Giuseppe Taurino, MS, Matteo Grioni, Francesca Ferlenghi, PhD, Livia Ruffini, MD, Federica Vacondio, PhD, Franca Zanardi, PhD, Matteo Bellone, MD, Rosa Maria Moresco, PhD, Ovidio Bussolati, MD PhD

Blood (2019) 134 (Supplement_1): 5542.

https://doi.org/10.1182/blood-2019-127935

Published: 2019

Journal Articles

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Angelina Yong, BSc,BMBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5504.

https://doi.org/10.1182/blood-2019-129754

Published: 2019

Journal Articles

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Carlos García, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brener Sabando, MD, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Kenny Galvez, MD, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Raimundo Gazitua, MD, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Macarena Roa, MD, Eloisa Riva, MD

Blood (2019) 134 (Supplement_1): 5497.

https://doi.org/10.1182/blood-2019-127555

Published: 2019

Journal Articles

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Shakira J. Grant, MBBS, Lindsay M. Hannan, MD MSPH, Jessica L. Brand, PhD, Robert E. Richard, MD PhD, Daniel Y. Wu, MD, Solomon A. Graf, MD, Jonathan Grim, MD PhD, Nicholas Burwick, MD, Thomas R. Chauncey, MD PhD

Blood (2019) 134 (Supplement_1): 5883.

https://doi.org/10.1182/blood-2019-122580

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

Does Trauma Heighten the Risk of Hematologic Malignancies? a Retrospective Study of U.S. Combat Veterans

Christin Destefano, MD, Krista Shaw, MS III, Ian Stewart, Eduard Poltavskiy, Kevin Chung, Lauren Walker, Nathan Boggs, Ying Suo, Adi Gundlapalli

Blood (2019) 134 (Supplement_1): 4130.

https://doi.org/10.1182/blood-2019-122994

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

Blood (2019) 134 (Supplement_1): 3064.

https://doi.org/10.1182/blood-2019-126527

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

NARROW

An IgA plasmacytoma: a rare and distinct form of plasmacytoma

Cutaneous plasmablastic plasmacytoma

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow Samples

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Does Trauma Heighten the Risk of Hematologic Malignancies? a Retrospective Study of U.S. Combat Veterans

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only